Wall Street Fundamentals Releases New In-Depth Stock Reports on CUR, KIN, PTCT and RGDO


Follow this company

Companies Mentioned

NYSE:CUR / NASDAQ:KIN / NASDAQ:PTCT / NASDAQ:RGDO
04/11/2014 [ACCESSWIRE]

U.S. markets were dragged lowered Thursday by a continued sell-off in the Biotech and Technology Sectors. The S&P 500 Index declined 2.09 percent to close at 1,833.08, while the Nasdaq Composite Index fell 3.10 percent, the most since 2011, to settle at 4,054.11. "There’s still a continual rotation out of the high-flying momentum stocks of 2013 into more value-driven opportunities," said Stifel Nicolaus portfolio manager Chad Morganlander. "This will continue in the coming weeks as investors look for consistency in earnings. You have concerns about high valuations and flat revenue growth, which is a perfect cocktail for a sector rotation out of growth and into value." Here is how some Biotech companies reacted Thursday:

Neuralstem, Inc. (NYSEMKT: CUR) shares traded in the range of $4.07 to $4.51 Thursday before settling to close at $4.11, a decrease of 11.80 percent. The stock appears to be facing some resistance at the $4.11 and $4.27 levels with some support at $3.77 and $3.50. Shares of Neuralstem have gained approximately 41.0 percent year-to-date.

More information on Neuralstem and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/CUR

Kindred Biosciences Inc. (NASDAQ: KIN) shares traded in the range of $15.30 to $17.84 Thursday before settling to close at $15.45, a decrease of 13.45 percent. The stock appears to be facing some resistance at the $16.91 and $18.96 levels with some support at $14.66 and $12.16. Shares of Kindred Biosciences are up approximately 38.0 percent year-to-date.

More information on Kindred Biosciences and access to the free equity report can be found at:      
www.WallStreetFundamentals.com/KIN

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares traded in the range of $19.92 to $24.20 Thursday before settling to close at $20.39, a decrease of 13.16 percent. The stock appears to be facing some resistance at the $21.63 and $22.77 levels with some support at $19.34 and $17.29. Shares of PTC Therapeutics are up approximately 20.0 percent year-to-date.

More information on PTC Therapeutics and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/PTCT

Regado Biosciences Inc. (NASDAQ: RGDO) shares traded in the range of $6.94 to $8.75 Thursday before settling to close at $7.17, a decrease of 18.34 percent. The stock appears to be facing some resistance at the $7.68 and $8.90 levels with some support at $6.91 and $6.51. Shares of Regado Biosciences are up approximately 50.0 percent year-to-date.

More information on Regado Biosciences and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/RGDO

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com

COMMENTS

Leave a comment...
 * 

Your Name
 *